2 ms·
Having been through the early phases of this (both as bench scientist and management, up through Phase II) I can say that this author's analysis is right on. T
by gumby 8y ago
Having been through the early phases of this (both as bench scientist and management, up through Phase II) I can say that this author's analysis is right on.
There is a macro wrinkle he doesn't mention and that makes things worse: as we increasingly succeed on stopping the big killers (e.g. lung cancer, CIs, various accidents that constituted most of the causes of death into the 1990s) the histogram of death starts to flatten out. That is, an increasingly larger set of conditions kill people, each condition killing a smaller number. At the limit, everybody would die of a unique condition.
This "problem" has been well understood for decades. The current model doesn't really work as this process continues, but nobody really knows yet what would be a reasonable replacement. This is one reason you see more and more ads for drugs that don't solve anything life threatening but have a larger prevalence (e.g. incontinence, insomnia, et al).
- 0815test 8y ago> This "problem" has been well understood for decades. The current model doesn't really work as this process continues, but nobody really knows yet what would be a reasonable replacement. Instead of targeting individual conditions, we'll probably see increased emphasis on common factors that can exacerbate many conditions, but aren't really considered "diseases" per se. The accumulation of changes due to aging would be a plausible candidate.
- SirLuxuryYacht 8y ago> histogram of death Not something you read everyday! How does your "wrinkle" make things necessarily worse? All [men] must die (sorry) at some point so succeeding at removing the biggest killers would give more people a second chance to die of something else later. Just because we cure cancer won't mean that there are suddenly more causes of death, just that the people who would have died from cancer will die of a variety of other existing things. Anyway, your point likely still stands. It makes sense that companies will have to spread resources across a diversifying research field once the big killers become treatable. edit: format
- jessriedel 8y ago> How does your "wrinkle" make things necessarily worse? If a small number of causes continued to be responsible for a large fraction of all deaths even as causes were defeated/delayed by medical interventions, then a continuous application of research resources could plausibly lead to consistent increases in life expectancy. For instance, if as heart disease deaths are being reduced by endovascular procedures those people are dying mostly of colon cancer, then we could divert resources to colon cancer research and hope for continued progress. But if, once the major diseases are suppressed, the number of causes of death explodes into a diverse spectrum of unique illnesses, there is little hope that constant (or reasonably increasing) resources can do much.
- gowld 8y agoIt's not absolutely worse, but the first derivative is worse -- marginal improvements get worse ROI as time passes and progress gets made.
- aaavl2821 8y agoThat's an interesting point, but I wonder how big of a problem it is? The way drug R&D dollars are currently allocated, it actually seems like we are steepening the histogram of death These days it is actually easier and more financially viable to develop drugs for rare diseases than highly prevalent diseases. 58% of new FDA approved drugs in 2018 were for orphan disease [0]. This is consistent with other measures like % of pharma M&A, % of venture deals across indications, etc. This suggests that it's more profitable to develop drugs for rare disease -- otherwise we'd see more funding for more prevalent disease Since we focus more on rare disease, we won't be making as much headway on "big killers". And since developing drugs for rare disease is more profitable, it seems the drug development model may actually work better in a world with more rare diseases. Looking at some CDC numbers [1], in 1980 85% of total deaths were caused by a top 10 cause of death. In 2015, 74% of all deaths were caused by a top 10 cause of death. Cancer and heart disease are still up at the top, and cancer deaths have increased 43% since 1980 (with US population growth of 42%). We will make more progress on cancer, but the "big killers" will remain so for a while, esp as little is spent on cardiovascular disease R&D or mental health (which shows up in the top 10 as suicide, which in 90% of cases is mental-illness related, and "unintentional injuries" which include a lot of drug overdoses). Rare disease in aggregate would probably make the top 10 causes of death. It would be interesting to see how rare-disease related mortality has changed in the last decades [0] http://www.hbmpartners.com/media/docs/industry-reports/Analysis-of-FDA-Approvals-2018-and-Previous-Years.pdf http://www.hbmpartners.com/media/docs/industry-reports/Analy... [1] https://www.cdc.gov/nchs/data/hus/hus16.pdf#019 https://www.cdc.gov/nchs/data/hus/hus16.pdf#019
- hef19898 8y agoReminds me if improving process performance, getting from 60% to 80% is easy, 80 to 90ish already hard, 90-95% really hard and everything above 98% is either luck or killing single deviations or both. Not counting for all the new causes that pop up. Anyway, it is an interesting angle, also economic wise. As causes are getting narrower all the time the increasing development costs can be shared by a lot less patients. I can see the incentive of not going after these treatments.